Edwards Lifesciences
About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Employees: 15,800
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 13 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
85% more call options, than puts
Call options by funds: $216M | Put options by funds: $117M
80% more first-time investments, than exits
New positions opened: 162 | Existing positions closed: 90
9% more capital invested
Capital invested by funds: $36.1B [Q1] → $39.1B (+$3.07B) [Q2]
4% more funds holding
Funds holding: 1,182 [Q1] → 1,230 (+48) [Q2]
0.44% more ownership
Funds ownership: 85.0% [Q1] → 85.44% (+0.44%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 9 [Q1] → 9 (+0) [Q2]
7% less repeat investments, than reductions
Existing positions increased: 416 | Existing positions reduced: 445
Research analyst outlook
13 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$79
2%
downside
Avg. target
$87
8%
upside
High target
$95
17%
upside
13 analyst ratings
7 positive
54%
6 neutral
46%
0 negative
0%
Wells Fargo Larry Biegelsen | 9%upside $88 | Overweight Maintained | 7 Aug 2025 |
JP Morgan Robbie Marcus | 5%upside $85 | Neutral Maintained | 25 Jul 2025 |
Canaccord Genuity William Plovanic | 0%upside $81 | Hold Maintained | 25 Jul 2025 |
Mizuho Anthony Petrone | 17%upside $95 | Outperform Maintained | 25 Jul 2025 |
Truist Securities Richard Newitter | 1%upside $82 | Hold Maintained | 25 Jul 2025 |
Financial journalist opinion
Based on 9 articles about EW published over the past 30 days
Neutral
Business Wire
6 days ago
Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to repurchase $500 million of Edwards' common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025. Under the terms of this ASR, Edwards will receive an initial delivery of approximately 5 million shares and the remainder at the maturity of the ASR. The final number of shares to be repurchased will be ba.
Neutral
GlobeNewsWire
1 week ago
Edwards Lifesciences Corporation Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Neutral
GlobeNewsWire
1 week ago
EDWARDS (EW) ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partners Encourage Investors Who Suffered Losses In Edwards (EW) To Contact Him Directly To Discuss Their Options
Positive
Seeking Alpha
2 weeks ago
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divestiture of non-core assets, new leadership, and a focus on high-growth hospital monitoring technologies. Eli Lilly remains a core holding due to its leadership in diabetes and obesity treatments, robust pipeline, and potential to triple revenues by 2030.
Neutral
GlobeNewsWire
2 weeks ago
JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition
IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition by Edwards Lifesciences.
Negative
Reuters
2 weeks ago
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve
The U.S. Federal Trade Commission sued to block Edwards Lifesciences Corp's acquisition of JenaValve Technology Inc, saying in a lawsuit filed in Washington on Wednesday the merger would decrease competition in the market for a device meant to treat a potentially fatal heart condition.
Neutral
Business Wire
2 weeks ago
Edwards Lifesciences Comments on FTC's Action to Block Proposed Acquisition of JenaValve
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition of JenaValve Technology. Edwards disagrees with FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation (AR). The company further believes the acquisition of JenaValve will accelerate the availability, adoption and continued innovation of.
Neutral
Benzinga
2 weeks ago
Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027
Edwards Lifesciences EW has just entered Phase 18, the final stage of its 18-phase Adhishthana cycle on the weekly chart. While the stock's setup doesn't necessarily point to a bearish outlook, the structure suggests that sluggish, range-bound price action could dominate through early 2027.
Positive
Market Watch
3 weeks ago
10 stocks favored to gain up to 30% in a sector that has missed this year's rally
All but two of the S&P 500's sectors are up so far in 2025.
Positive
Benzinga
1 month ago
Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance
Edwards Lifesciences' EW stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by significant growth across its heart valve therapies.
Charts implemented using Lightweight Charts™